Creative Planning Amgen Inc Transaction History

Creative Planning

$101 Billion
Q3 2024

A detailed history of Creative Planning transactions in Amgen Inc stock. As of the latest transaction made, Creative Planning holds 197,457 shares of AMGN stock, worth $56.8 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

197,457

Previous 182,593 8.14%

Holding current value

$56.8 Million

Previous $57.1 Million 11.52%

% of portfolio

0.06%

Previous 0.06%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 11, 2024	BUY	$309.38 - $337.38 $4.6 Million - $5.01 Million	14,864 Added 8.14%	197,457 $63.6 Million
Q2 2024 Aug 15, 2024	BUY	$262.75 - $319.31 $3.7 Million - $4.5 Million	14,082 Added 8.36%	182,593 $57.1 Million
Q1 2024 May 10, 2024	BUY	$268.87 - $324.56 $1.64 Million - $1.97 Million	6,082 Added 3.74%	168,511 $47.9 Million
Q4 2023 Feb 14, 2024	BUY	$255.7 - $288.46 $1.03 Million - $1.16 Million	4,020 Added 2.54%	162,429 $46.8 Million
Q3 2023 Nov 16, 2023	BUY	$218.65 - $271.46 $3.33 Million - $4.13 Million	15,216 Added 10.63%	158,409 $42.6 Million
Q2 2023 Jul 21, 2023	BUY	$214.27 - $253.37 $784,228 - $927,334	3,660 Added 2.62%	143,193 $31.8 Million
Q1 2023 May 15, 2023	SELL	$225.79 - $275.2 $463,546 - $564,985	-2,053 Reduced 1.45%	139,533 $33.7 Million
Q4 2022 Feb 10, 2023	BUY	$229.03 - $291.01 $2.7 Million - $3.43 Million	11,797 Added 9.09%	141,586 $37.2 Million
Q3 2022 Nov 03, 2022	SELL	$224.46 - $253.15 $1.74 Million - $1.96 Million	-7,759 Reduced 5.64%	129,789 $29.3 Million
Q2 2022 Aug 15, 2022	BUY	$230.71 - $256.74 $6.32 Million - $7.03 Million	27,384 Added 24.86%	137,548 $33.5 Million
Q1 2022 May 16, 2022	SELL	$219.27 - $242.57 $218,831 - $242,084	-998 Reduced 0.9%	110,164 $26.6 Million
Q4 2021 Feb 11, 2022	SELL	$198.88 - $227.6 $756,340 - $865,562	-3,803 Reduced 3.31%	111,162 $25 Million
Q3 2021 Nov 10, 2021	SELL	$212.27 - $248.7 $547,656 - $641,646	-2,580 Reduced 2.19%	114,965 $24.4 Million
Q2 2021 Aug 04, 2021	BUY	$233.58 - $259.14 $1.58 Million - $1.75 Million	6,764 Added 6.11%	117,545 $28.7 Million
Q1 2021 Apr 30, 2021	BUY	$221.91 - $258.6 $545,010 - $635,121	2,456 Added 2.27%	110,781 $27.6 Million
Q4 2020 Jan 29, 2021	SELL	$216.38 - $257.67 $46,088 - $54,883	-213 Reduced 0.2%	108,325 $24.9 Million
Q3 2020 Nov 05, 2020	BUY	$234.65 - $260.95 $1.96 Million - $2.18 Million	8,347 Added 8.33%	108,538 $27.6 Million
Q2 2020 Jul 23, 2020	SELL	$197.81 - $242.74 $571,077 - $700,790	-2,887 Reduced 2.8%	100,191 $23.6 Million
Q1 2020 May 05, 2020	SELL	$182.24 - $241.7 $566,219 - $750,961	-3,107 Reduced 2.93%	103,078 $20.9 Million
Q4 2019 Jan 30, 2020	BUY	$189.21 - $243.2 $690,427 - $887,436	3,649 Added 3.56%	106,185 $25.6 Million
Q3 2019 Nov 01, 2019	SELL	$174.11 - $208.62 $336,554 - $403,262	-1,933 Reduced 1.85%	102,536 $19.8 Million
Q2 2019 Jul 26, 2019	BUY	$166.7 - $195.41 $892,011 - $1.05 Million	5,351 Added 5.4%	104,469 $19.3 Million
Q1 2019 Apr 24, 2019	SELL	$180.87 - $203.88 $104,000 - $117,231	-575 Reduced 0.58%	99,118 $18.8 Million
Q4 2018 Feb 01, 2019	BUY	$178.4 - $208.25 $430,836 - $502,923	2,415 Added 2.48%	99,693 $19.4 Million
Q3 2018 Oct 25, 2018	BUY	$185.29 - $208.89 $788,779 - $889,244	4,257 Added 4.58%	97,278 $20.2 Million
Q2 2018 Jul 20, 2018	BUY	$166.05 - $186.51 $784,918 - $881,632	4,727 Added 5.35%	93,021 $17.2 Million
Q1 2018 Apr 18, 2018	SELL	$169.43 - $198.0 $1.36 Million - $1.59 Million	-8,013 Reduced 8.32%	88,294 $15.1 Million
Q4 2017 Jan 17, 2018	BUY	$168.79 - $188.59 $1.42 Million - $1.58 Million	8,391 Added 9.54%	96,307 $16.7 Million
Q3 2017 Oct 17, 2017	BUY	$167.29 - $191.0 $14.7 Million - $16.8 Million	87,916	87,916 $16.4 Million

Others Institutions Holding AMGN

# of Institutions

3,121

Shares Held

410M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $154B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.

Account

Creative Planning Amgen Inc Transaction History